PEA15: Phosphoprotein Enriched in Astrocytes 15
A multifunctional adaptor protein involved in apoptosis, glucose metabolism, and cell proliferation.
Gene Information Card
| Symbol | PEA15 |
|---|---|
| Full Name | Phosphoprotein Enriched in Astrocytes 15 |
| Gene Type | protein-coding |
| Chromosomal Location | 1q23.1 |
| NCBI Gene ID | 8682 ncbi.nlm.nih.gov/gene/8682 |
| Ensembl ID | ENSG00000134250 |
| UniProt ID | Q15121 |
| OMIM ID | 603890 |
| HGNC ID | 8822 |
| Aliases | HMAT1, MAT1, PEA-15, PED |
Description
PEA15 (Phosphoprotein Enriched in Astrocytes 15) encodes a 15 kDa death effector domain (DED)-containing protein that regulates apoptosis, glucose transport, and cell cycle progression. It is widely expressed, with highest levels in brain astrocytes. The protein interacts with FADD and caspase-8 to inhibit death receptor-mediated apoptosis, and also modulates ERK/MAPK signaling and GLUT4 translocation.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Type 2 Diabetes | PEA15 (PED) overexpression impairs insulin-stimulated GLUT4 translocation, contributing to insulin resistance. | PMID: 10725249; OMIM 603890 |
| Astrocytoma | PEA15 is highly expressed in astrocytomas and may promote tumor cell survival by inhibiting apoptosis. | PMID: 14522991; COSMIC |
| Breast Cancer | PEA15 overexpression correlates with poor prognosis and resistance to chemotherapy via anti-apoptotic effects. | PMID: 19029981; COSMIC |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 45.2 | High |
| Heart | 12.8 | Medium |
| Liver | 8.5 | Low |
| Skeletal Muscle | 15.3 | Medium |
| Pancreas | 6.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| U-87 MG (glioblastoma) | 52.1 | High expression; astrocytic origin |
| MCF7 (breast cancer) | 18.4 | Moderate expression |
| HepG2 (hepatocellular carcinoma) | 9.7 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G (p.Met1?) | Missense | <0.1% | Likely loss of start codon; effect unknown |
| c.112G>A (p.Ala38Thr) | Missense | <0.1% | Rare variant; functional impact uncertain |
Mutation functional classification
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported in PEA15.
Gain of Function (GOF)
Overexpression of wild-type PEA15 is associated with anti-apoptotic and insulin-resistant phenotypes.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • apoptotic process | • negative regulation of apoptotic process |
| • positive regulation of glucose import | • signal transduction |
| • protein binding | • death effector domain binding |
Pathways
• FAS signaling pathway (CD95)
• Insulin signaling pathway
• MAPK signaling pathway
Protein Summary
PEA15 is a 130-amino acid protein containing a death effector domain (DED) that mediates interactions with FADD and caspase-8, inhibiting extrinsic apoptosis. It also binds ERK1/2 and RSK2, modulating MAPK signaling. In insulin-responsive tissues, PEA15 (also called PED) impairs GLUT4 translocation, contributing to insulin resistance. The protein is highly expressed in astrocytes and astrocytomas, where it promotes cell survival.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PEA15 Knockout HEK293 Cell Line | EDJ-KQ3588 | Human | 8682 | Details Get a Quote |
| PEA15 Knockout HCT 116 Cell Line | EDJ-KQ24112 | Human | 8682 | Details Get a Quote |
| PEA15 Knockout A-549 Cell Line | EDJ-KQ25488 | Human | 8682 | Details Get a Quote |
| PEA15 Knockout HeLa Cell Line | EDJ-KQ25490 | Human | 8682 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
